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Abstract
Patients with acute coronary syndrome (ACS) require long-term antithrombotic intervention to reduce the risk of further 
ischemic events; dual antiplatelet therapy with a  P2Y12 inhibitor and acetylsalicylic acid (ASA) is the current standard of 
care. However, pivotal clinical trials report that patients receiving this treatment have a residual risk of approximately 10% 
for further ischemic events. The development of non-vitamin K antagonist oral anticoagulants (NOACs) has renewed interest 
in a ‘dual pathway’ strategy, targeting both the coagulation cascade and platelet component of thrombus formation. In the 
phase III ATLAS ACS 2 TIMI 51 trial, a ‘triple therapy’ approach (NOAC plus dual antiplatelet therapy) showed reduced 
ischemic events with rivaroxaban 2.5 mg twice daily, albeit at an increased risk of bleeding. Two studies have investigated 
the role of NOACs in combination with a  P2Y12 inhibitor, with or without ASA, in reducing bleeding risk in patients with 
atrial fibrillation undergoing percutaneous coronary intervention; two further studies are underway. Although these trials 
will help to inform optimal treatment protocols for secondary prevention of ACS, an individualized approach to treatment 
will be needed, taking account of the high frequency of co-morbid conditions found in this patient population.
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Key Points 
Dual antiplatelet therapy with a  P2Y12 inhibitor and 
acetylsalicylic acid is the current standard of care for 
patients with acute coronary syndrome; however, a resid-
ual risk of approximately 10% for recurrent ischemic 
events and death persists.
Triple therapy with a non-vitamin K antagonist oral anti-
coagulant (NOAC) plus dual antiplatelet therapy reduces 
the risk of ischemic events, albeit at an increased risk of 
bleeding.
Studies are now focused on dual targeting of platelet and 
thrombin activation pathways with a NOAC plus single 
antiplatelet therapy.
1 Introduction
Admissions for acute coronary syndrome (ACS) in the USA 
accounted for > 1.3 million unique hospitalizations in 2006, 
with annual costs estimated at US$54,821 per patient [1]. 
Rehospitalization with a cardiovascular diagnosis cost an 
average of US$9510 per patient, with 30% of patients rehos-
pitalized at least once within the first 12 months after index 
ACS admission. In Europe, hospital discharge rates for coro-
nary heart disease per 100,000 population increased from 
532 in 2001 to 608 in 2012 [2], and the estimated annual 
cost (2004) per patient with ACS ranges from €7009 (UK) 
to €12,086 (Italy). The largest contributor to total costs was 
hospital stay [3].
Despite optimal standard care and secondary prevention, 
patients remain at high risk of further ischemic coronary 
events and death in the months and years after an index 
ACS event [4, 5]. This article examines a ‘dual antiplatelet’ 
approach for secondary prevention in patients with ACS and 
explores the evidence base for a ‘dual strategy’ approach in 
this setting.
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2  Antithrombotic Approaches to Secondary 
Prevention
Thrombus formation after atherosclerotic plaque rupture 
involves both platelet activation and fibrin generation 
(Fig. 1) [6, 7]. Furthermore, elevated thrombin generation 
persists long after the index ACS event [8], supporting long-
term risk-reduction strategies [5]. Platelet activation and 
coagulation are highly interdependent processes. Throm-
bin is central to both, by stimulating platelet activation and 
aggregation and catalyzing fibrinogen conversion to fibrin, 
stabilizing the thrombus [9, 10]. This interdependency sup-
ports a ‘dual pathway’ strategy targeting the coagulation 
cascade and the platelet component of thrombus formation.
Historical data confirm the efficacy of targeting the 
dual pathway in reducing ischemic events after ACS [11]. 
Meta-analysis data show that, versus acetylsalicylic acid 
(ASA) alone, ASA plus warfarin significantly reduced 
the risk of death, myocardial infarction (MI), or stroke 
in patients with an international normalized ratio of 2–3 
(p < 0.0001). However, major bleeding risk was increased 
[11] and led to the restriction of combined anticoagulant 
and antiplatelet therapy to patients with ACS and a firm 
indication for oral anticoagulation, such as paroxysmal, 
persistent, or permanent atrial fibrillation (AF), and a 
 CHA2DS2–VASc (Cardiac failure, Hypertension, Age ≥ 75 
[2 points], Diabetes, Stroke [2 points]–Vascular disease, 
Age 65–74, Sex category) score ≥ 2 [12]. The long-term 
standard of care for antithrombotic treatment after ACS 
remains ‘dual antiplatelet therapy’ with potent  P2Y12 
inhibitors (clopidogrel, prasugrel, and ticagrelor) plus 
ASA [12, 13], based on trial data showing clinical benefit 
when added to ASA.
The first trial demonstrating clinical benefit was the 
CURE (Clopidogrel in Unstable Angina to Prevent Recur-
rent Events) trial, where addition of clopidogrel to various 
doses of ASA reduced the rate of cardiovascular death, MI, 
or stroke versus ASA alone. As might be expected, bleeding 
risk increased with increasing ASA dose [14].
Subsequent trials have demonstrated the superiority 
of prasugrel and ticagrelor over clopidogrel in reducing 
ischemic events, albeit with increased bleeding. The TRI-
TON–TIMI 38 (TRial to Assess Improvement in Thera-
peutic Outcomes by Optimizing Platelet InhibitioN with 
Prasugrel–Thrombolysis In Myocardial Infarction 38) trial 
of > 13,000 patients with ACS undergoing percutaneous 
coronary intervention (PCI) compared prasugrel and ASA 
with clopidogrel and ASA. The composite of cardiovas-
cular death, non-fatal MI, or non-fatal stroke occurred in 
9.9% of patients receiving prasugrel and in 12.1% receiving 
clopidogrel (p < 0.001). Non-coronary artery bypass graft 
(CABG)-related Thrombosis in MI (TIMI) major bleeding 
was more frequent with prasugrel (2.4% vs. 1.8%, respec-
tively; p = 0.03), as was fatal bleeding [15].
Vascular death, MI, or stroke occurred in 9.8% 
of > 18,000 patients with ACS in the PLATO (PLATelet 
inhibition and patient Outcome) trial administered tica-
grelor plus ASA versus 11.7% treated with clopidogrel 
plus ASA (p < 0.001). Major bleeding rates between the 
groups were similar. However, non-CABG-related TIMI 
major bleeding was more frequent with ticagrelor (2.8% 
vs. 2.2%, respectively; p = 0.03), as was fatal intracranial 
bleeding [16].
These studies established the role of  P2Y12 inhibitors as 
the mainstay of antithrombotic therapy in ACS. However, 
although TRITON–TIMI 38 and PLATO showed superiority 
over clopidogrel in reducing post-ACS ischemic events, they 
revealed a residual risk of recurrent cardiovascular events 
and death of ~ 10% despite ‘optimal’ dual antiplatelet ther-
apy [17]. Therefore, new approaches to further reduce the 
residual risk of subsequent ischemic events, while minimiz-
ing bleeding risk, are required.
More recently, studies have explored novel therapeutic 
agents targeting different pathways of the coagulation cas-
cade and adding a new agent to a dual antiplatelet regimen.
Fig. 1  Current concepts of the 
coagulation process (reproduced 
with permission from De Cate-
rina et al. [6]). ADP adenosine 
diphosphate, GP glycoprotein, 
PAR protein-activated recep-
tor, TF tissue factor, vWF von 
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Vorapaxar, a protease-activated receptor-1 antagonist, 
inhibits thrombin-induced platelet aggregation. In the 
phase  III TRACER (Thrombin Receptor Antagonist for 
Clinical Event Reduction in Acute Coronary Syndrome) 
trial, 12,944 patients with ACS received vorapaxar or 
placebo plus standard antiplatelet therapy, predominantly 
clopidogrel plus ASA [18]. Vorapaxar increased moderate 
or severe bleeding (7.2% vs. 5.2%; p < 0.001) and intracra-
nial bleeding (1.1% vs. 0.2%; p < 0.001) in GUSTO (Global 
Utilization of Streptokinase and t-PA [tissue plasminogen 
activator] for Occluded Coronary Arteries), without improv-
ing ischemic outcomes. The composite of cardiovascular 
death, MI, stroke, recurrent ischemia with rehospitalization, 
or urgent coronary revascularization was not significantly 
reduced with vorapaxar (18.5% vs. 19.9%; p = 0.07) [18].
Several non-vitamin K antagonist (VKA) oral anticoagu-
lants (NOACs), including apixaban, darexaban, letaxaban, 
and rivaroxaban (direct Factor Xa inhibitors) and dabi-
gatran (a direct thrombin inhibitor), have been evaluated in 
post-ACS, secondary prevention trials. The APPRAISE-2 
(Apixaban for Prevention of Acute Ischaemic Events-2) [19], 
RUBY-1 [20], AXIOM-ACS [21], ATLAS ACS 2 TIMI 51 
(Anti-Xa Therapy to Lower Cardiovascular Events in Addi-
tion to Aspirin With or Without Thienopyridine Therapy 
in Subjects with Acute Coronary Syndrome–Thrombolysis 
in Myocardial Infarction 51) [22], and RE-DEEM [23] tri-
als tested these agents in combination with dual antiplatelet 
therapy (Table 1).
The phase III ATLAS ACS 2 TIMI 51 trial [22] rand-
omized over 15,500 patients with ACS to receive rivar-
oxaban 2.5 or 5 mg twice daily (doses based on phase II 
ATLAS ACS TIMI 46 trial [24]) or placebo in addition to 
ASA with or without clopidogrel or ticlopidine in accord-
ance with local guidelines. The findings led to approval of 
rivaroxaban in Europe in combination with ASA alone or 
ASA and clopidogrel (or ticlopidine) in selected patients 
with ACS at low risk of bleeding; rivaroxaban remains the 
only NOAC currently approved for this indication [12].
In contrast, other trials [19–21, 23] with NOACs in a tri-
ple therapy regimen failed to show net clinical benefit. The 
phase III APPRAISE-2 trial aimed to investigate the efficacy 
and safety of apixaban in addition to standard antiplatelet ther-
apy in patients with a recent ACS and at least two additional 
risk factors for ischemic events. The trial was terminated 
early because apixaban 5 mg twice daily plus antiplatelet 
therapy led to an increase in the number of major bleeding 
events in this patient population, without a significant reduc-
tion in recurrent ischemic events [19]. These NOAC trials 
demonstrate the need for ‘optimal balance’ between reducing 
ischemic events and increasing bleeding risk when combining 
anticoagulant and antiplatelet therapies in patients with ACS.
The phase II GEMINI-ACS-1 trial took a different 
approach to secondary prevention and compared rivaroxa-
ban 2.5 mg twice daily plus a  P2Y12 inhibitor with ASA 
plus a  P2Y12 inhibitor in patients with ACS [25]. The risk of 
TIMI non-CABG clinically significant bleeding was similar 
in both trial arms. The rate of the exploratory endpoint of 
Table 1  Endpoints of the ATLAS ACS 2 TIMI 51, APPRAISE-2, RE-DEEM, RUBY-1, and AXIOM-ACS trials
bid twice daily, CABG coronary artery bypass grafting, CV cardiovascular, MI myocardial infarction, NS not significant, od once daily, TIMI 
thrombolysis in myocardial infarction
a Kaplan–Meier estimates
Trial Ischemic events Bleeding events
ATLAS ACS 2 TIMI 51 
[22]
CV death, MI, or stroke: 9.1% with rivaroxaban 
2.5 mg bid vs. 10.7% with placebo (p = 0.02)a
Non-CABG-related bleeding: 1.8% with rivaroxaban 2.5 mg bid 
vs. 0.6% with placebo (p < 0.001)a
Intracranial hemorrhage: 0.4% with rivaroxaban 2.5 mg bid vs. 
0.2% with placebo (p = 0.04)a
APPRAISE-2 [19] CV death, MI, or ischemic stroke: 7.5% with 
apixaban vs. 7.9% with placebo (p = NS)
Major bleeding: 1.3% with apixaban vs. 0.5% with placebo 
(p = 0.001)
RE-DEEM [23] CV death, non-fatal MI, or non-hemorrhagic 
stroke: 4.6, 4.9, 3.0, and 3.5% with dabigatran 
50, 75, 110, and 150 mg bid, respectively, vs. 
3.8% with placebo
Major or clinically relevant minor bleeding: 3.5, 4.3, 7.9, and 
7.8% with dabigatran 50, 75, 110, and 150 mg bid, respectively, 
vs. 2.2% with placebo (p < 0.001 for dabigatran 110 and 150 mg 
bid vs. placebo)a
RUBY-1 [20] All-cause death, non-fatal MI, non-fatal stroke, or 
severe recurrent ischemia: 6.5% with darexaban 
vs. 5.2% with  placeboa
Major or clinically relevant non-major bleeding: 5.6–7.3% (od) 
and 6.8–11.3% (bid) with darexaban 10–60 mg/day vs. 3.1% 
with placebo (overall p = 0.02)a
AXIOM-ACS [21] CV death, non-fatal MI, non-fatal stroke, or myo-
cardial ischemia requiring hospitalization: 4.8% 
with letaxaban 20–240 mg/day vs. 4.4% with 
placebo (p = NS)
TIMI major bleeding: 0.9% with letaxaban 20–240 mg/day vs. 
0.5% with placebo (p = NS)
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the composite of cardiovascular death, MI, stroke, or defi-
nite stent thrombosis was also similar between the treatment 
arms.
The role of ASA has been questioned because of con-
cerns over increased bleeding with triple therapy. WOEST 
(What is the Optimal antiplatElet and anticoagulant therapy 
in patients with oral anticoagulation and coronary StenTing), 
a small-scale, open-label study [26], compared clopidogrel 
alone (dual therapy) with clopidogrel plus ASA (triple 
therapy) in patients already receiving long-term oral anti-
coagulation who had undergone PCI [26]. Compared with 
triple therapy, dual therapy had a lower rate of any bleeding 
(19.4% vs. 44.4%; p < 0.0001) and a lower rate of death, MI, 
stroke, target vessel revascularization, or stent thrombosis 
(11.1% vs. 17.6%; p = 0.025) [26]. A large meta-analysis 
was conducted to compare the safety and efficacy of dual 
therapy with triple therapy in patients on oral anticoagu-
lants undergoing PCI, and obtained similar findings to the 
WOEST study; there was an increased risk of major bleed-
ing events with triple therapy compared with dual therapy 
[27]. The WOEST 2 registry (ClinicalTrials.gov identifier 
NCT02635230) plans to recruit 2200  patients with AF 
undergoing coronary revascularization, treated with an oral 
anticoagulant and a  P2Y12 inhibitor with or without ASA, 
with completion scheduled for 2019. Despite its limitations, 
WOEST was the first study to suggest that combining an 
anticoagulant with a  P2Y12 inhibitor alone may be suitable 
for long-term secondary prevention after an ACS event in 
patients with no prior indication for long-term anticoagulant 
therapy such as AF.
In the PIONEER AF-PCI (Prevention of Bleeding in 
Patients with Atrial Fibrillation Undergoing PCI) trial [28] 
of patients with AF undergoing PCI, over 50% of patients 
had a history of ACS in the preceding 12 months (Fig. 2). 
This study confirmed the safety, in terms of reduced TIMI 
major and minor bleeding, of rivaroxaban 2.5 mg twice daily 
with dual antiplatelet therapy and rivaroxaban 15 mg once 
daily with single antiplatelet therapy versus warfarin plus dual 
antiplatelet therapy. The trial was not powered to show supe-
riority or non-inferiority for the reduction in major adverse 
cardiovascular events. Following the PIONEER AF-PCI trial, 
up to 12 months’ treatment with rivaroxaban 15 mg once daily 
(or 10 mg once daily in patients with moderate renal impair-
ment) plus a  P2Y12 inhibitor was approved by the European 
Medicines Agency for use in patients with non-valvular AF 
who undergo PCI with stent placement; however, the approval 
document highlighted that data in this population were limited 
and no data were available in such patients with a history of 
stroke or transient ischemic attack [29].
Similarly, the RE-DUAL PCI (Dual Antithrombotic Ther-
apy with Dabigatran after PCI in Atrial Fibrillation) trial com-
pared two dabigatran-based (110 or 150 mg twice daily) dual 
antithrombotic therapy regimens with warfarin-based triple 
therapy in patients with AF after PCI (Fig. 3) [30]. Dabigatran 
plus a  P2Y12 inhibitor was associated with a significantly 
lower rate of major or clinically relevant non-major bleed-
ing than warfarin plus a  P2Y12 inhibitor plus ASA. The trial 
also found that when data from both dabigatran arms were 
pooled, the dual-therapy regimens were non-inferior to the 
triple-therapy regimen in terms of efficacy.
European guidance supports triple therapy for the short-
est time possible for patients with ACS and AF undergoing 
PCI [12, 31]. Furthermore, European guidelines on the use 
of dual antiplatelet therapy in coronary artery disease state 
that dual therapy with clopidogrel and an oral anticoagu-
lant should be considered in place of triple therapy when a 
patient with an indication for anticoagulation has a bleed-
ing risk that outweighs their ischemic risk [31]. However, 
these recommendations are based partly on expert opinion, 
because prospective studies of triple therapy in these patients 
are limited, although further trials are currently recruiting 
(Table 2).
N=2124
End of treatment
(12 months) 
1:1:1
R
Rivaroxaban 15 mg oda,b + single antiplatelet
Rivaroxaban 2.5 mg bidb
+ DAPTc
VKA (INR 2.0–3.0)d
+ DAPTc VKA + low-dose ASA
Rivaroxaban 15 mg oda
+ low-dose ASA
Population: Patients with 
paroxysmal, persistent 
or permanent NVAF 
undergoing PCI (with 
stent placement)
Intended DAPT duration
of 1, 6 or 12 months
Fig. 2  Design of the PIONEER AF-PCI trial [42]. aCreatinine clear-
ance 30–49  mL/min: 10  mg od. bFirst dose 72–96  h after sheath 
removal. cASA (75–100 mg/day) plus clopidogrel (75 mg/day) (alter-
native use of prasugrel or ticagrelor allowed, but capped at 15%). 
dFirst dose 12–72  h after sheath removal. ASA acetylsalicylic acid, 
bid twice daily, DAPT dual antiplatelet therapy, INR international 
normalized ratio, NVAF non-valvular atrial fibrillation, od once daily, 
PCI percutaneous coronary intervention, R randomization, VKA vita-
min K antagonist
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3  Discussion and Future Perspectives
The development of NOACs, which have demonstrated 
fewer intracranial bleeding events and deaths than VKAs 
in AF trials [32], has renewed interest in a dual pathway 
strategy for the secondary prevention of ACS, targeting 
both the coagulation cascade and the platelet component 
of thrombus formation [7, 33].
The disparate outcomes of the only two phase III trials 
(ATLAS ACS 2 TIMI 51 and APPRAISE-2) conducted 
to date in patients with ACS deserve further discussion. 
The apixaban dose in APPRAISE-2 was the same as that 
recommended for use in patients with AF, whereas the 
rivaroxaban dose in ATLAS ACS 2 TIMI 51 was adjusted 
to 25–50% of the AF dose [22]. The lower rivaroxaban 
dose (2.5 mg twice daily) exhibited the best efficacy and 
safety profile [22].
The importance of dose selection for patients with ACS 
may be partly explained by the ‘dual property’ of throm-
bin. Thrombin is anticoagulatory at low concentrations but 
a procoagulant at high concentrations, a scenario known 
as the ‘thrombin paradox’ [34]. The GUSTO IIb trial of 
patients with ACS showed elevated thrombin generation in 
the 12 months post index event [8]. However, the correla-
tion between thrombin generation and clinical events was 
non-linear, with higher rates of cardiac death or MI seen at 
both very low and very high thrombin levels, complicating 
the search for an optimal post-ACS anticoagulant dose [34].
In addition, compared with ATLAS ACS 2 TIMI 51, 
APPRAISE-2 patients were older and more likely to 
have diabetes mellitus and/or renal dysfunction, and 
N=2725
Follow-up every
3 months for
≥6 months; mean
duration 14 months
R
Dabigatran 110 mg bida + a P2Y12 inhibitorb
Dabigatran 150 mg bida + a P2Y12 inhibitorb
Warfarin (INR 2.0–3.0) + ASAc + a P2Y12 inhibitor
Population: patients with
paroxysmal, persistent or
permanent NVAF who had
received successful PCI
within the previous 120 hours
Mean treatment duration 12.3 months
Fig. 3  Design of the RE-DUAL PCI trial [30]. Non-US patients 
aged ≥ 80  years and Japanese patients aged ≥ 70  years were rand-
omized to receive dabigatran 110  mg bid dual therapy or warfarin-
based triple therapy in accordance with the respective product labels 
in these countries. aFirst dose within 120  h after PCI. bClopidogrel 
(75  mg od) or ticagrelor (90  mg bid) for at least 12  months after 
randomization. cASA ≤ 100 mg od was stopped at 1 or 3 months in 
patients who received bare-metal stent or drug-eluting stent implanta-
tion, respectively. ASA acetylsalicylic acid, bid twice daily, INR inter-
national normalized ratio, NVAF non-valvular atrial fibrillation, od 
once daily, PCI percutaneous coronary intervention, R randomization
Table 2  Ongoing trials in patients with atrial fibrillation undergoing percutaneous coronary intervention
ACS acute coronary syndrome, AF atrial fibrillation, ASA acetylsalicylic acid, bid twice daily, CRNM clinically relevant non-major, od once 
daily, PCI percutaneous coronary intervention, VKA vitamin K antagonist
a ASA for 1–12 months guided by clinical presentation
Trial details AUGUSTUS ENTRUST AF-PCI
ClinicalTrials.gov identifier NCT02415400 NCT02866175
Study phase IV III
Patient population AF + ACS or PCI with stenting AF + PCI with stenting
Interventions Apixaban 2.5 or 5 mg bid + P2Y12 inhibitor ± ASA Edoxaban 60 mg (or 30 mg) 
od + P2Y12 inhibitor
VKA + P2Y12 inhibitor ± ASA VKA + P2Y12 inhibitor + ASAa
Primary endpoint Major or CRNM bleeding Major or CRNM bleeding
Secondary endpoints Death, ischemic events Death, ischemic events
Target enrollment (n) 4600 1500
Expected completion December 2018 November 2018
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non-ST-elevation MI versus ST-elevation MI as their index 
event [19, 22, 33]. Furthermore, ATLAS ACS 2 TIMI 51 
excluded patients with prior stroke or transient ischemic 
attack who were already receiving ASA plus a  P2Y12 inhibi-
tor [22, 33]. The higher-risk population of APPRAISE-2 
may have been less responsive to anticoagulant therapy than 
the ATLAS ACS 2 TIMI 51 population [22, 33].
The benefit–risk profile of dabigatran in patients with 
ACS can only be determined in an adequately powered 
phase III trial. To date, no such trial has been scheduled; 
however, the two highest dabigatran doses used in the 
phase II RE-DEEM trial significantly increased major and 
clinically relevant minor bleeding, and were identical to 
those used in patients with AF [23, 33].
The recently completed PIONEER AF-PCI [28] and 
RE-DUAL PCI [35] trials and the ongoing AUGUSTUS 
(NCT02415400) and ENTRUST AF-PCI (NCT02866175) 
trials should help to determine the treatment regimens with 
the optimal benefit–risk profile in patients with ACS and 
AF. The trials will also provide additional information on 
the appropriate duration of antiplatelet therapy and intensity 
of oral anticoagulation in patients with ACS and AF [28], 
and on the feasibility of removing ASA from the treatment 
regimen [33].
Most patients with ACS have co-morbidities and risk fac-
tors that put them at increased risk of ischemic or bleeding 
events [36]. Therefore, individualized assessment of bleed-
ing risk and risk of coronary stent thrombosis are important 
considerations in guiding the duration of triple therapy [12, 
31, 37, 38] and stent type in patients requiring PCI.
Renal impairment occurs in approximately 30–40% 
of patients with ACS and is an independent predictor of 
increased mortality and major bleeding [36]. Although the 
same antiplatelet regimens are recommended regardless 
of renal function status, dose adjustments of oral antico-
agulants are usually recommended for those with moderate 
renal impairment [12, 37]. Dabigatran is unlikely to be the 
first-choice NOAC in patients with moderate renal impair-
ment because it is primarily excreted via the kidneys [37]. 
Minimal data are available in patients with severe renal 
impairment, and no prospective data exist for patients with 
end-stage renal disease or who are on hemodialysis [37].
Diabetes is present in 20–30% of patients with ACS and 
is an independent predictor of mortality [12, 36]. Although 
guidelines recommend that patients with diabetes receive 
the same antithrombotic regimens as those without diabetes 
[12], treatment of this patient population remains subopti-
mal [36]. In a subanalysis, TRITON–TIMI 38, patients with 
diabetes received a greater net clinical benefit from prasugrel 
versus clopidogrel than non-diabetic patients [39]. However, 
no such interaction with diabetic status was found in the 
PLATO trial with ticagrelor [40] or ATLAS ACS 2 TIMI 51 
with rivaroxaban [22].
Female sex is a predictor of major bleeding in ACS, and 
women have an increased risk of recurrence of ischemic 
events at 6 months [36]. Current guidelines recommend that 
men and women with ACS are managed similarly; however, 
some studies have suggested that women are less likely to 
receive evidence-based care [12].
Patients aged ≥ 75 years with ACS have an increased 
risk of recurrent ischemic events, bleeding, and mortality, 
with 60% of all ACS-related deaths occurring in this age 
group [41]. However, again, they are less likely to receive 
evidence-based therapies [12]. Although prasugrel is 
generally not recommended in elderly patients after TRI-
TON–TIMI 38 did not find a net clinical benefit in this age 
group [15], the PLATO trial [41] did not find significant 
differences in efficacy and safety in elderly patients receiv-
ing ticagrelor. Guidelines recommend that close attention 
be paid to specific contraindications in elderly patients, as 
well as renal function. Individualized benefit–risk assess-
ments in this age group should take account of estimated 
life expectancy, co-morbidities, quality of life, and patient 
preferences [12].
4  Conclusion
Despite optimal secondary prevention after ACS, a residual 
ongoing risk of recurrent ischemic events remains up to 
and beyond 12 months. Trials of triple therapy (oral anti-
coagulant plus dual antiplatelet therapy) targeting the dual 
pathway have shown reduced ischemic events, albeit at an 
increased risk of bleeding. Ongoing studies are focusing on 
dual therapy (oral anticoagulant plus single antiplatelet ther-
apy) to target the platelet- and fibrin-mediated pathways of 
thrombus formation for ACS secondary prevention. Several 
trials are underway, particularly in patients with concomitant 
AF, and will provide important data on the optimal inten-
sity of oral anticoagulation, the optimal antiplatelet therapy 
regimen, the use of oral anticoagulation combined with new 
 P2Y12 inhibitors, and the efficacy and safety of NOACs ver-
sus VKAs. Many patients with ACS have co-morbidities, 
which require consideration to enable optimal treatment and 
long-term outcomes. The addition of anticoagulation may 
enable an individualized approach to the use of antithrom-
botic agents for secondary prevention of ACS. Algorithms 
to simplify choice between the increased treatment options 
may help clinicians assess benefits and risks of each treat-
ment strategy and balance the risk of thrombotic events with 
the risk of bleeding [36].
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